CERo Therapeutics Holdings, Inc. Highlights Progress
Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN ...
Cero Therapeutics reports current cash position of $8M
CEO Chris Ehrlich commented, “We have had a very strong entry into 2025, which has greatly improved the outlook of the Company from the ...